Hikma Pharmaceuticals Plc (HIK) Earns Hold Rating from Peel Hunt
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “hold” rating reaffirmed by Peel Hunt in a report released on Wednesday. They presently have a GBX 1,390 ($18.28) price objective on the stock. Peel Hunt’s target price suggests a potential upside of 46.39% from the stock’s previous close.
Several other equities analysts also recently commented on the stock. J P Morgan Chase & Co lowered their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($19.73) to GBX 1,250 ($16.44) and set a “neutral” rating for the company in a research note on Friday, October 6th. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 1,560 ($20.52) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. Jefferies Group LLC lowered their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.28) to GBX 1,045 ($13.74) and set a “hold” rating for the company in a research note on Monday, August 21st. Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc to an “equal weight” rating and lowered their price objective for the company from GBX 2,050 ($26.96) to GBX 1,600 ($21.04) in a research note on Wednesday, August 2nd. Finally, Stifel Nicolaus downgraded shares of Hikma Pharmaceuticals Plc to a “hold” rating and lowered their price objective for the company from GBX 2,300 ($30.25) to GBX 1,320 ($17.36) in a research note on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 1,321.91 ($17.39).
Hikma Pharmaceuticals Plc (LON HIK) opened at GBX 949.50 ($12.49) on Wednesday. Hikma Pharmaceuticals Plc has a one year low of GBX 934 ($12.28) and a one year high of GBX 2,346 ($30.86).
TRADEMARK VIOLATION WARNING: “Hikma Pharmaceuticals Plc (HIK) Earns Hold Rating from Peel Hunt” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/15/hikma-pharmaceuticals-plc-hik-earns-hold-rating-from-peel-hunt.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.